Karyopharm Therapeutics (NASDAQ:KPTI) Target Lowered by Morgan Stanley to $27.00

Karyopharm Therapeutics stock has undergone multiple analysts rating changes in the recent past.  stock Target Lowered by Morgan Stanley on 10/12/2021. In a note to investors, the firm issued a new target price of $27.00. The analysts previously had $29.00 target price. Morgan Stanley’s price target would indicate a potential upside of 356.85% from the stock’s previous close.

Shares of traded on monday, reaching $5.87. 127583 shares of the stock traded hands, compared to its average volume of 1239943. On monday, Shares of closed at $5.87. The firm’s 50 day moving average is $5.75 and its 200 day moving average is $10.13.  has a 12 month low of $4.42 and a 12 month high of $18.00. While on yearly highs and lows, today has traded high as $6.00 and has touched $5.84 on the downward trend.

Earnings and What to expect: 

Karyopharm Therapeutics last posted its quarterly earnings data on August 5th, 2021. The reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.01. The business had revenue of $22.60 million for the quarter, compared to analysts’ expectations of $26.86 million. Karyopharm Therapeutics has generated ($2.72) earnings per share over the last year (($2.80) diluted earnings per share). Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($2.81) to ($2.07) per share. Karyopharm Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 1st, 2021 based off prior year’s report dates.

Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($2.81) to ($2.07) per share. The P/E ratio of Karyopharm Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Karyopharm Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Karyopharm Therapeutics has a P/B Ratio of 8.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

(NASDAQ:KPTI) Moving Average Technical Analysis

5 day Moving Average is $$5.78 And 5 day price change is $0.18 (3.14%)  with average volume for 5 day average is 912,780. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $5.95 and 20 day price change is -$0.08 (-1.34%) and average 20 day moving volume is 1,227,580. 50 day moving average is $5.75  and 50 day price change is -$2.42 ( -29.05%)  and with average volume for 50 days is : 1,642,632. 200 day moving average is $10.13  and 200 day price change is -$10.53 (-64.05%)  and with average volume for 200 days is : 1,907,241.

Other owners latest trading in Karyopharm Therapeutics :

  • On 9/17/2021 shares held by Virtu Financial LLC were 18,229 which equates to market value of $0.19M and appx 0.00% owners of Karyopharm Therapeutics
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 172,474 which equates to market value of $1.78M and appx 0.00% owners of Karyopharm Therapeutics
  • On 8/30/2021 shares held by Integral Health Asset Management LLC were 150,000 which equates to market value of $1.55M and appx 0.40% owners of Karyopharm Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 78.06% for Karyopharm Therapeutics

See More Analyst Rating at: RATING